Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Results

Rhythm Pharmaceuticals Misses on EPS — Stock Down 0.52%

Rhythm Pharmaceuticals reported a loss per share that was slightly worse than expected, which contributed to a modest decline in the stock price. The lack of revenue data and guidance may raise concerns among investors about the company's short-term outlook. Overall, the market reacted negatively, reflecting uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.76	N/A	-0.13%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding current market conditions. They are prioritizing long-term growth initiatives while navigating recent challenges.

Management acknowledged the ongoing challenges in the market.

They emphasized focusing on long-term strategies despite short-term setbacks.

Rhythm Pharmaceuticals Misses on EPS — Stock Down 0.52%

Key numbers

Management commentary

Rhythm Pharmaceuticals, Inc.

More earnings this week

Rhythm Pharmaceuticals Misses on EPS — Stock Down 0.52%

Key numbers

Management commentary